课题基金 / 基金详情

Research in the inhibitory effect of sarcoplasmic reticulum Ca release channel stabilizer on the development of heart failure

Research in the inhibitory effect of sarcoplasmic reticulum Ca release channel stabilizer on the development of heart failure
肌浆网钙释放通道稳定剂抑制心力衰竭发展的研究
批准号:
13670717
负责人:
YANO Masafumi
金额:
$2.56万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2002

项目摘要

项目成果

YANO Masafumi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
In heart failure, abnormal function of sarcoplasmic reticulum (SR) is one of the major pathogenic mechanisms in heart failure. Here, we assessed the effects of 1,4-benzothiazepine derivative JTV519 (intracellular Ca2+ modulator) and propranolol on cardiac and SR functions. SR vesicles were isolated from dog LV muscles {normal (N), n=11; 4-weeks rapid RV pacing with or without JTV519 (JT:14.4 mg/Kg/day) or propranolol (PL:0.05mg/kg/day) [untreated: n=10, JT(+): n=10, PL(+): n=10, respectively]}. 1) In either JT(+) or PL(+), cardiac function was improved compared with untreated group. 2) Abnormal SR Ca2+ leak was found in untreated failing SR. A benzothiazepine Ca^<2+> antagonist diltiazem as well as JTV519 acutely inhibited this Ca^<2+> leak in failing SR (IC50= 0.3μM, 0.03μM, respectively), and neither nifedipine nor verapamil affected the Ca^<2+> leak. There was no abnormal SR Ca^<2+> leak either in JT(+) and PL(+). 3) Both JTV519 and propranolol prevented the decrease in the stoichiometry of RyR vs FKBP12.6 assessed by [^3H]ryanodine and [^3H]FK 506-bindng assays [1:3.6 in normal, 1:1.3 in untreated, 1:3.6 in JT(+), 1:2.4 in PL(+)]. 4) In untreated group, RyR was PKA- hyperphosphorylated, whereas it was reversed both in JT(+) and in PL(+). 5) The amount of RyR-bound FKBP12.6 was tremendously less in untreated group than normal RyR, whereas it was reversed both in JT(+) and PL(+). 6) RyR was labeled in a site-directed fashion with the fluorescent conformational probe methylcoumarin acetate (MCA). In both J(+) and P(+), the level of MCA fluorescence, which was higher in untreated group, was decreased back towards normal, suggesting the improvement of RyR conformational state by both treatments. Both JTV519 and proplanolol improved cardiac function and attenuated LV remodeling by ameliorating the defective interaction of FKBP12.6 with RyR through restoration of PKA-hyperphosphorylation of RyR and the following conformational change of RyR.
期刊论文(12)
专著(0)
科研奖励(0)
会议论文
Takayuki Hisaoka: "Enhancement of Rho/Rho-kinase system in regulation of vascular smooth muscle contraction in tachycardia-induced heart failure"Cardiovascular Research. 49. 319-329 (2001)
Takayuki Hisaoka:“增强 Rho/Rho 激酶系统对心动过速引起的心力衰竭中血管平滑肌收缩的调节”心血管研究。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Masahiro Doi: "Propranolol prevents the development of heart failure by restoring FKBP12.6-mediated stabilization of ryanodine receptor"Circulation. 105. 1374-1379 (2002)
Masahiro Doi:“普萘洛尔通过恢复 FKBP12.6 介导的兰尼定受体的稳定性来预防心力衰竭的发展”。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Doi M., Yano M., Kobayashi S., et al.: "Propranolol prevents the development of heart failure by restoring FKBP12.6-mediated stabilization of ryanodine receptor"Circulation. 105. 1374-1379 (2002)
Doi M.、Yano M.、Kobayashi S. 等人:“普萘洛尔通过恢复 FKBP12.6 介导的兰尼碱受体稳定性来预防心力衰竭的发生”循环。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Masateru Kohno: "A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure"American Journal of Physiology. 284. H1035-H1042 (2003)
Masateru Kohno:“一种新的心脏保护剂 JTV519 可改善心力衰竭中兰尼碱受体的通道门控缺陷”《美国生理学杂志》。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
10
    Comprehensive treatment of heart failure, cardiac hypertrophy, and arrhythmia by controlling ryanodine receptor bound calmodulin
    • 批准号:
      17H04178
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $10.73万
    • 财政年份:
      2017
    • 负责人:
      YANO Masafumi
    • 依托单位:
    An attempt to regress cardiac hypertrophy by cardiomyocyte intracellular calmodulin control
    • 批准号:
      16K15443
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.25万
    • 财政年份:
      2016
    • 负责人:
      YANO Masafumi
    • 依托单位:
    New molecular targeting therapy for regression of cardiac hypertrophy by inhibiting abnormal Ca2+ leak through RyR2 in hypertrophic cardiomyopathy
    • 批准号:
      26670404
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.33万
    • 财政年份:
      2014
    • 负责人:
      YANO Masafumi
    • 依托单位:
    Comprehensive strategy of heart failure, cardiac hypertrophy and lethal arrhythmia via stabilizing the stricture of ryanodine receptor
    • 批准号:
      26293189
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $10.65万
    • 财政年份:
      2014
    • 负责人:
      YANO Masafumi
    • 依托单位:
    海外基金